Literature DB >> 12891059

Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-alpha are potent inducers of HIV-specific CD8 T cells.

Cédric Carbonneil1, Albertine Aouba, Marianne Burgard, Sylvain Cardinaud, Christine Rouzioux, Pierre Langlade-Demoyen, Laurence Weiss.   

Abstract

OBJECTIVE: To investigate the ability of granulocyte-macrophage colony-stimulating factor (GM-CSF) and IFN-alpha to induce the differentiation of peripheral monocytes into dendritic cells (DC) and their ability to trigger an HIV-specific CD8 T-cell response.
METHODS: Monocytes isolated from both seronegative controls and HIV-infected individuals were differentiated into DC using GM-CSF with either IL-4 or IFN-alpha for 7 days. We assessed the phenotypic characteristics and IL-12 production by flow cytometry. The ability of DC to trigger CD8 T-cell responses was assessed by means of ELISpot and cytotoxicity assays. In addition, HIV-1-RNA levels were measured in culture supernatants.
RESULTS: Compared with control DC generated in the presence of GM-CSF and IL-4, DC generated in the presence of GM-CSF and IFN-alpha expressed higher levels of MHC class I molecules and produced similar or higher levels of IL-12 after CD40 ligation or Staphyloccus aureus Cowan stimulation. GM-CSF/IFN-alpha DC expressed low levels of CD4, CXCR4 and DC-SIGN and did not produce detectable virus during the differentiation period. Pulsed GM-CSF/IFN-alpha DC were found to prime CD8 T cells from HIV-negative controls to exert cytotoxic activity against target cells expressing HIV antigens. HIV peptide-pulsed GM-CSF/IFN-alpha DC promote specific IFN-gamma production by autologous CD8 T cells from HIV-seronegative donors. Furthermore, GM-CSF/IFN-alpha DC from HIV-seropositive patients efficiently present HIV peptides to autologous CD8 T lymphocytes.
CONCLUSION: GM-CSF and IFN-alpha allow the generation of DC with high CD8 T-cell stimulating abilities. Therefore, this strategy may represent a novel approach to therapeutic vaccination in HIV disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12891059     DOI: 10.1097/00002030-200308150-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

1.  Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Authors:  Delphine Pannetier; Stéphanie Reynard; Marion Russier; Alexandra Journeaux; Noël Tordo; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  Mucosal vaccine delivery: Current state and a pediatric perspective.

Authors:  Akhilesh Kumar Shakya; Mohammed Y E Chowdhury; Wenqian Tao; Harvinder Singh Gill
Journal:  J Control Release       Date:  2016-02-06       Impact factor: 9.776

Review 3.  Decoding the complexity of type I interferon to treat persistent viral infections.

Authors:  Elizabeth B Wilson; David G Brooks
Journal:  Trends Microbiol       Date:  2013-11-08       Impact factor: 17.079

4.  Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals.

Authors:  Ellen R Van Gulck; Guido Vanham; Leo Heyndrickx; Sandra Coppens; Katleen Vereecken; Derek Atkinson; Eric Florence; Ilse Kint; Zwi Nisan Berneman; Viggo Van Tendeloo
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

5.  Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway.

Authors:  Rong Wang; Aizhang Xu; Xueying Zhang; Jie Wu; Andrew Freywald; Jianqing Xu; Jim Xiang
Journal:  Cell Mol Immunol       Date:  2016-06-06       Impact factor: 11.530

6.  Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes.

Authors:  Rong Wang; Andrew Freywald; Yue Chen; Jianqing Xu; Xin Tan; Jim Xiang
Journal:  Cell Mol Immunol       Date:  2014-09-08       Impact factor: 11.530

Review 7.  Type I interferons as regulators of human antigen presenting cell functions.

Authors:  Sandra Gessani; Lucia Conti; Manuela Del Cornò; Filippo Belardelli
Journal:  Toxins (Basel)       Date:  2014-05-26       Impact factor: 4.546

8.  Comparison of morphology, phenotypes and function between cultured human IL‑4‑DC and IFN‑DC.

Authors:  Zhiliang Jin; Jing Fan; Yajuan Zhang; Yongxiang Yi; Lili Wang; Dandan Yin; Tao Deng; Wei Ye
Journal:  Mol Med Rep       Date:  2017-09-21       Impact factor: 2.952

Review 9.  Anti-inflammatory properties of Type I interferons.

Authors:  Alfons Billiau
Journal:  Antiviral Res       Date:  2006-04-04       Impact factor: 5.970

Review 10.  Granulocyte macrophage colony-stimulating factor has come of age: From a vaccine adjuvant to antiviral immunotherapy.

Authors:  Maria Petrina; Jacqueline Martin; Sameh Basta
Journal:  Cytokine Growth Factor Rev       Date:  2021-01-09       Impact factor: 7.638

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.